NutraGenesis LLC is pleased to announce the launch of Orisett™, the new benchmark nutraceutical for advanced blood glucose management. Orisett is a breakthrough, naturally derived, patent-pending nutraceutical designed to define the benchmark for the glucose management category. Containing low molecular weight chitosan oligosaccharide bioactives derived from crab shells, clinically proven Orisett helps promotes both long-term blood sugar maintenance as well as short-term post-prandial responses via multiple mechanisms of action. Orisett was developed and manufactured by NutraGenesis supply partner Kunpoong Bio Co., Ltd. of South Korea, a leading international supplier of chitosan oiligosaccharides.
Orisett’s efficacy and safety have been demonstrated in short-term and long-term “gold standard”, randomized, double-blind, placebo-controlled human clinical trials involving healthy subjects, as well as pre-clinical research.
“We are very excited about the launch of Orisett into the North American marketplace and the vast potential for this state-of-the-art ingredient,” said NutraGenesis President Suzanne McNeary. “With the glucose management category predicted to grow to $240 million by 2019, clinically proven Orisett has the potential to gain significant market share”.
Orisett may be utilized as either a standalone ingredient or as the featured proprietary ingredient in glucose maintenance and metabolic wellness dietary supplements formulations. Orisett can enhance the novel, specialty status of a wide variety of product applications including: capsules, tablets, nutrition bars, stick packs, drink mixes, gummies and more.